XIG: FHIR Resources

FHIR IG Statistics: FHIR Resources

Version: All | R2 | R2B | R3 | R4 | R4B | R5 | R6
Authority: All | hl7 | ihe | national
Realm: All | BNW | au | be | br | ca | ch | cl | cr | cz | de | dk | ee | eu | fi | fr | il | in | it | jp | kr | nl | no | nz | pl | se | sl | stt | tw | uk | us | uv | vn
View: All | Resource Profiles | Datatype Profiles | Extensions | Logical Models | CodeSystems | ValueSets | ConceptMaps

Resources - ValueSet

29,056 resources

By Version

R2: 0
R2B: 0
R3: 1,154
R4: 23,662
R4B: 244
R5: 3,968
R6: 28

By Authority

none: 8,611
hl7: 17,881
ihe: 218
national: 1,286
who: 1,060

By Realm

none: 5,874
au: 87
be: 108
br: 73
ca: 244
ch: 395
cl: 150
cr: 11
cz: 48
de: 680
dk: 475
ee: 66
eu: 349
fi: 4
fr: 810
il: 144
in: 48
it: 92
jp: 71
nl: 958
no: 6
nz: 17
pl: 23
se: 10
tw: 161
uk: 23
us: 13,139
uv: 4,925
vn: 23
other: 5

Start Prev Rows 5800 - 6000 Next

Package	Version	Identity	Name/Title	Status	Date	Realm	Auth
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.182	Cladribine Injectable	active	2021-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.183	Daratumumab Injectable	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.184	Durvalumab Injectable	active	2024-11	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.185	Emapalumab Injectable	active	2024-11	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.186	Fludarabine Injectable	active	2021-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.187	Ipilimumab Injectable	active	2024-11	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.188	Nivolumab Injectable	active	2024-11	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.189	Pembrolizumab Injectable	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.190	Polatuzumab Vedotin Injectable	active	2021-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.191	Pralatrexate Injectable	active	2021-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.192	Vincristine Injectable	active	2021-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.193	Methotrexate Injectable	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.194	Trastuzumab Injectable	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.195	Mitomycin Injectable	active	2021-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.196	Brentuximab Vedotin Injectable	active	2021-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.197	Doxorubicin Pegylated Liposomal Injectable	active	2024-11	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.198	Blinatumomab Injectable	active	2024-11	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.199	Trastuzumab Emtansine Injectable	active	2021-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.200	Gemtuzumab Ozogamicin Injectable	active	2021-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.201	Tagraxofusp Injectable	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.202	Axicabtagene Ciloleucel Injectable	active	2024-11	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.203	BRCA1	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.204	BRCA2	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.205	BRCA1 Testing	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.207	Epithelial Ovarian Cancer	active	2024-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.208	Primary Peritoneal Cancer	active	2022-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.209	Fallopian Tube Cancer	active	2022-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.210	Multigene Panel	active	2023-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.211	BRCA1 and BRCA2	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.212	BRCA1 and BRCA2 Testing	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.213	BRAF V600	active	2022-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.214	BRAF V600 Testing	active	2023-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.215	Colorectal Cancer	active	2024-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.216	BRAF V600 Mutation Status	active	2022-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.217	Cancer Stage I	active	2024-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.218	Head and Neck Cancer	active	2022-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.219	Malignant Melanoma of Skin	active	2022-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.220	Brain Cancer	active	2022-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.221	Waldenstrom Macroglobulinemia	active	2024-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.222	High Emetic Risk Intravenous Antineoplastic Agent	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.223	Moderate Emetic Risk Intravenous Antineoplastic Agent	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.224	Docetaxel Injectable	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.225	Cyclophosphamide Injectable	active	2022-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.226	LAG 3 Inhibitor	active	2024-11	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.233	Chemotherapy Administration	active	2024-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.240	Pathological N Stage N3c	active	2024-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.241	Audio Visual Telehealth Encounter	active	2025-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.242	Moderate or High Emetic Risk Oral Antineoplastic Agent	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.243	Minimal to Low Emetic Risk Oral Antineoplastic Agent	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.244	Copanlisib Injectable	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.245	Isatuximab Injectable	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.246	Loncastuximab tesirine Injectable	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.247	Margetuximab Injectable	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.248	Mirvetuximab soravtansine Injectable	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.249	Tafasitamab Injectable	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.250	Teclistamab Injectable	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.251	Tisotumab Injectable	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.252	Asparaginase Injectable	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.254	Belantamab Injectable	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.255	Dostarlimab Injectable	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.256	Mosunetuzumab Injectable	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.257	Tremelimumab Injectable	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.258	Indication for Dexamethasone	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.260	Indication for Olanzapine	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.261	Indication for Dexamethasone	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.263	Indication for Olanzapine	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.264	Prednisone	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.265	As Needed PRN	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.266	Amivantamab Injectable	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.200	Doxorubicin	active	2020-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.201	Epirubicin	active	2020-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.202	Capecitabine	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.203	Cyclophosphamide	active	2020-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.204	Injectable Fluorouracil	active	2020-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.205	Methotrexate	active	2020-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.206	Trastuzumab and Biosimilars	active	2020-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.207	HER2 Presence in Tissue	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.208	Carboplatin	active	2020-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.209	Depression Screening for Adult	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.210	Long Acting Opioids	active	2020-10	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.211	High Fiber Supplement or Diet Education	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.212	Dexamethasone	active	2021-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.213	Olanzapine	active	2021-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.214	Pancreatic Cancer	active	2020-10	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.215	Audio Visual Telehealth Encounter	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.216	Telephone Encounter	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.217	Telehealth Emergency Department or Initial Inpatient	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.218	Dyspnea Assessment	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.219	Nausea or Vomiting Assessment	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.220	Karnofsky Performance Status	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.221	Referral to Hospice Care	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.222	Referral to Palliative Care	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.223	Palliative Care	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.224	Enrollment in Hospice Care	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.225	Advance Directive Including Durable Power of Attorney or Instructional	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.229	Minimal Emetic Risk Intravenous Antineoplastic Agent	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.232	Epithelial Ovarian Cancer	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.233	Primary Peritoneal Cancer	active	2022-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.235	BRCA2 Testing	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.236	Multigene Panel	active	2023-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.237	BRCA1 Testing	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.238	First Line Drug Therapy for Metastatic Colorectal Cancer	active	2022-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.239	BRAF V600 Testing	active	2022-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.240	Cancer Stage 4	active	2022-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.241	Cancer Stage M1	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.242	High Emetic Risk Intravenous Antineoplastic Agent	active	2022-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.243	Moderate Emetic Risk Intravenous Antineoplastic Agent	active	2024-10	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.245	Antiemetic Agent	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.247	Indication for Dexamethasone	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.249	Indication for Olanzapine	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.2074.1.1.3	Race Category Excluding Nulls	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.1002.77	Codeine	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.1004.13	Dihydrocodeine	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.1004.14	Nalbuphine	active	2020-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4009	Malignant Intracranial Neoplasm	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4010	Malignant Intracranial Neoplasm	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4015	STEMI	active	2022-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4016	STEMI	active	2019-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4017	STEMI	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4019	Fibrinolytic Therapy	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4023	Cerebral Vascular Lesion	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4024	Cerebral Vascular Lesion	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4025	Cerebral Vascular Lesion	active	2019-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4026	Closed Head and Facial Trauma	active	2019-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4028	Aortic Dissection or Ruptured Aortic Aneurysm	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4029	Acute Peptic Ulcer	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4030	Acute Peptic Ulcer	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4031	Acute Peptic Ulcer	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4032	Dementia and Related Intracranial Pathologies	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4033	Dementia and Related Intracranial Pathologies	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4034	Active Bleeding or Bleeding Diathesis, Excluding Menses	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4035	Active Bleeding or Bleeding Diathesis, Excluding Menses	active	2022-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4036	Active Bleeding or Bleeding Diathesis, Excluding Menses	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4043	Dementia and Related Intracranial Pathologies	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4044	Aortic Dissection or Ruptured Aortic Aneurysm	active	2022-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4045	Oral Anticoagulant Medications	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4046	Cardiopulmonary Emergency	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4047	Cardiopulmonary Emergency	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4048	Cardiopulmonary Emergency	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4049	Mechanical Circulatory Assist Device	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4050	Mechanical Circulatory Assist Device	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4052	Mechanical Circulatory Assist Device	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4053	Pregnant State	active	2022-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4054	Pregnant State	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4055	Pregnant State	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3157.4056	Major Surgical Procedure	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3566.2.1005	Chronic Stable Angina	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3566.2.1006	Chronic Stable Angina	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.3566.3.1002	Chronic Stable Angina	active	2021-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.1001	Hospice Encounter	active	2021-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.1002	Hospice Encounter	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.1003	Hospice Encounter	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.1004	Nutrition Services	active	2021-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.1005	Nutrition Services	active	2021-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.1006	Nutrition Services	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.1007	Hospice Care Ambulatory	active	2021-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.1008	Hospice Care Ambulatory	active	2021-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1005	Office Visit	active	2023-11	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1020	Initial Hospital Inpatient Visit	active	2017-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1030	Discharge Services Hospital Inpatient Same Day Discharge	active	2017-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1035	Discharge Services Hospital Inpatient	active	2017-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1040	Outpatient Consultation	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1050	Emergency Department Evaluation and Management Visit	active	2017-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1060	Nursing Facility Visit	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1065	Discharge Services Nursing Facility	active	2017-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1080	Home Healthcare Services	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1110	Preventive Care, Initial Office Visit, 0 to 17	active	2017-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1115	Preventive Care Services Initial Office Visit, 18 and Up	active	2017-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1120	Preventive Care, Established Office Visit, 0 to 17	active	2017-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1125	Preventive Care Services Established Office Visit, 18 and Up	active	2017-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1130	Preventive Care Services Individual Counseling	active	2017-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1135	Preventive Care Services Group Counseling	active	2017-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1215	Referral	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1216	Face-to-Face Interaction	active	2017-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1221	Behavioral Health Follow up Visit	active	2020-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1222	Psychotherapy and Pharmacologic Management	active	2017-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1228	Detoxification Visit	active	2021-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1232	Audiology Visit	active	2017-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1233	Medical Disability Exam	active	2019-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1260	Telephone Visits	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1261	Nursing Facility Visit	active	2018-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1262	Care Services in Long Term Residential Facility	active	2018-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1264	Office Visit	active	2025-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1265	Home Healthcare Services	active	2021-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1266	Outpatient Consultation	active	2020-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1276	Frailty Encounter	active	2019-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1277	Outpatient Encounter	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1278	Outpatient Encounter	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1279	Frailty Encounter	active	2019-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1284	Outpatient Encounter	active	2023-11	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1285	Palliative Encounter	active	2025-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1286	Palliative Encounter	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.11.1287	Telephone Visits	active	2021-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.12.1001	Office Visit	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.12.1004	Initial Hospital Inpatient Visit	active	2017-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.12.1006	Discharge Services Hospital Inpatient Same Day Discharge	active	2017-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.12.1007	Discharge Services Hospital Inpatient	active	2017-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.12.1008	Outpatient Consultation	active	2024-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.12.1010	Emergency Department Evaluation and Management Visit	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.464.1003.101.12.1012	Nursing Facility Visit	active	2024-01	us	hl7